Correction of posaconazole concentrations for hypoalbuminemia.

This study focuses on correction of posaconazole concentrations for hypoalbuminemia.. The research employs high-performance liquid chromatography (HPLC) techniques to address analytical challenges in the clinical field. Posaconazole is an example of a highly protein-bound drug ( 98%) in which therapeutic drug monitoring (TDM) is commonplace. Total drug concentration is typically measured, and in the setting of hypoalbuminemia, total concentrations are lower despite no anticipated change in unbound concentration. Data support that unbound posaconazole concentration is responsible for... Research Background and Significance Posaconazole is a triazole antifungal agent widely used in clinical settings for prophylaxis and treatment of invasive fungal infections, especially among immunocompromised patients. Due to its high plasma protein binding ( 98%), primarily to albumin, therapeutic drug monitoring (TDM) is crucial for optimizing dosing and ensuring therapeutic efficacy. However, hypoalbuminemia—common in critically ill and oncologic patients—alters total plasma drug concentrations without necessarily affecting the pharmacologically active unbound fraction. This discrepancy poses a significant analytical and clinical challenge, as conventional TDM typically measures total drug concentration, potentially leading to misinterpretation of drug exposure and inappropriate dose adjustments. The study by Nix et al. addresses this challenge by employing validated high-performance liquid chromatography (HPLC) methods to accurately quantify posaconazole concentrations and apply corrections for hypoalbuminemia. Such corrections are vital for precise clinical decision-making and improved patient care. Experimental Design and Methodology The study implemented a robust HPLC methodology